A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

The study "Reducing MRI Use in Organised Prostate Cancer Testing Using Blood-Based Biomarkers - the OPT Stockholm3 Study" ...

Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

A world-first trial of Australian men has confirmed a specialised scan can accurately “light up” prostate cancer, saving ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...